louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT04623203: The Prognosis of Migraine and Tension-Type Headache in Children and Adolescents
Official title: The Prognosis of Migraine and Tension-Type Headache in Children and Adolescents
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Children, Only
Headache, Migraine
Headache, Tension
Keywords: Headache
Migraine
Tension Type Headache
Adolescents
Outcome
Lead sponsor: Bnai Zion Medical Center
Sponsor class: OTHER_GOV
First posted: 2020-11-10
Enrollment: 2000
Sex: ALL
Minimum age (years): 5
Maximum age (years): 18
Standard ages: CHILD
ADULT
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Children and adolescents that visited the pediatric neurology clinic at the Bnai Zion medical center do to migraine or TTH headache between the years 2007-2010

Brief summary: Children and adolescents that visited the pediatric neurology clinic at the Bnai Zion medical center do to migraine or TTH headache between the years 2007-2010 were reevaluated. We used a structured headache questionnaire through a phone interview with the patients and their caregivers. Data regarding demographics, the patients' and families' medical history, and headache history, past and current (age at onset, location, quality, frequency, duration of episodes, aura, associated symptoms and treatment) were collected.


Eligibility criteria: Inclusion Criteria:

* Diagnosis of migraine or TTH headache according to the ICHD-3 criteria.
* Can describe the current headache status.

Exclusion Criteria:

\* Secondary headaches.

Primary outcomes:
measure: Headache diagnosis according to the ICHD-3 criteria
timeFrame: 10 years from initial diagnosis
Secondary outcomes:
Other outcomes:
Locations:
city: Haifa
country: Israel
facility: Bnai Zion Medical Center
Study officials:
affiliation: Bnai Zion Medical Center
name: Jacob GENIZI
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00824603: Impact of Continuing Medical Education (CME) Insulin Program
Official title: Impact of CME Program on Self-Reported Confidence and Use of Insulin in Persons With Type 2 Diabetes
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Diabetes
Lead sponsor: HealthPartners Institute
Sponsor class: OTHER
Collaborators: name: International Diabetes Center at Park Nicollet
name: Eli Lilly and Company
name: Novo Nordisk A/S
name: United Health Care
name: Merck Sharp & Dohme LLC
First posted: 2009-01-19
Enrollment: 294
Sex: ALL
Minimum age (years): 25
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Primary care providers affiliated with the participating healthcare organizations were invited to attend.

Brief summary: The purpose of this study is to determine if a continuing medical education (CME) program can change primary care providers' use of insulin therapy - their confidence in selecting doses and engagement of patients in the decision making as to whether to initiate insulin therapy.

Detailed description: We will determine whether attendees' self-reported confidence and use of insulin with persons with type 2 diabetes changes after they attend the CME program. Specifically, we will address the following questions:

Question 1. Clinical guidelines. Is insulin initiated earlier (at a lower A1C)?

Question 2. Decision-making. Does confidence in selecting a starting insulin regimen change? Does confidence in selecting a starting insulin dose change? Does confidence in adjusting insulin change? Does confidence in discussion nutrition guidelines change?

Question 3. Application. Do more patients start using insulin? Who usually selects starting dose? How is starting dose selected? How often is insulin adjusted?

Question 4. Resources. How available are protocols for insulin use? How available is adequate time to monitor insulin therapy? How available is staff to teach insulin injections? How available is staff to help adjust insulin?

Eligibility criteria: Inclusion Criteria:

* primary care provider attending CME training

Exclusion Criteria:

-

Primary outcomes:
measure: We will determine whether attendees' self-reported confidence and use of insulin with persons with type 2 diabetes changes after they attend the CME program.
timeFrame: pre program survey & 2-4 month post program survey
Secondary outcomes:
measure: pre-CME training level of patient's A1c when starting insulin therapy compared to post-CME training level of patient's A1c when starting insulin therapy
timeFrame: pre program survey and 2-4 month post program survey
Other outcomes:
Locations:
city: Minneapolis
country: United States
facility: International Diabetes Center
state: Minnesota
Study officials:
affiliation: International Diabetes Center at Park Nicollet
name: Margaret Powers, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00615303: The Effectiveness of Simethicone In Improving Visibility During Colonoscopy
Official title: The Effectiveness of Simethicone In Improving Visibility During Colonoscopy: A Randomized, Placebo-controlled Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Colonoscopy
Keywords: Bowel preparation, colonoscopy, simethicone, air bubble
Lead sponsor: Ramathibodi Hospital
Sponsor class: OTHER
First posted: 2008-02-14
Enrollment: 194
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Sodium phosphate is one of the bowel preparation regimens for colonoscopy. However, intraluminal gas can impair visibility during the examination. Simethicone is medication that works by reducing the surface tension of air bubbles. We aimed to evaluate the effect of simethicone in enhancing visibility and efficacy during colonoscopy.

Detailed description: A prospective, randomized, double-blinded, placebo-controlled study was conducted. One hundred and twenty-four patients were allocated to receive 2 dosages of either 45 ml of sodium phosphate plus 240 mg of simethicone tablets or 45 ml of sodium phosphate plus placebo in the evening before and in the morning of the procedure day. The colonoscopic examination was recorded. Visibility was blindly assessed for the amount of air bubbles and the degree of haziness by a single investigator. Five areas of the colon were graded for the amount of air bubbles, from 0 to 3; grade 0 and 1 were defined as the diminishing of air bubbles. The haziness was graded into 5 levels from excellent to unacceptable. Excellent, good and adequate were defined as the diminishing of haziness. The total duration of colonoscopy, the side effect of medication and the endoscopist and patient satisfaction were compared between 2 groups. Endoscopist satisfaction was evaluated by questionnaires. Visual analog scale (0-10) was used for rating patient satisfaction and the side effect of medication.

Eligibility criteria: Inclusion Criteria:

- Patients with age 18-70 yrs old who undergo colonoscopy at the endoscopic unit of the hospital

Exclusion Criteria:

* Renal insufficiency (Cr \>2.3 mg/dl)
* Congestive heart failure
* Massive ascites
* Acute myocardial infarction within 6 months
* Coagulopathy
* Previous colonic surgery
* Suspected of colonic obstruction Pregnancy Refuse to give inform consent

Primary outcomes:
measure: Visibility: air bubble and haziness
timeFrame: During colonoscopy
Secondary outcomes:
measure: Total colonoscopic time, patient and doctor satisfaction and side effects
timeFrame: During colonscopy
Other outcomes:
Locations:
city: Bangkok
country: Thailand
facility: Ramathibodi hospital
Study officials:
affiliation: Ramathibodi Hospital
name: Abhasnee Sobhonslidsuk, M.D.
role: STUDY_DIRECTOR
References:
Clinical trial NCT03006003: Osteoporosis Treatment in Post-menopausal Women
Official title: The Assessment of Osteoporosis Treatment in Post-menopausal Women
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE4
Conditions: Depressive Syndrome
Keywords: Osteoporosis
Raloxifene
Central nervous disorders
Lead sponsor: Taichung Veterans General Hospital
Sponsor class: OTHER
First posted: 2016-12-30
Enrollment: 500
Sex: FEMALE
Minimum age (years): 20
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The study will be conducted to assess the depressive symptoms and related markers in the postmenopausal female after anti-osteoporosis treatment.

Detailed description: Fracture is one of the important complications in female. Osteoporosis should be treated in postmenopausal female due to high risk of fracture. Recently, there have been many classes of medications developed for preventing bone loss. Raloxifene, an oral form of anti-osteoporosis medication, has been reported to improved central nervous disorders. Therefore, this study is designed to assess the depressive symptoms and related markers in the postmenopausal female after anti-osteoporosis treatment.

Eligibility criteria: Inclusion Criteria:

* Postmenopausal female
* Osteoporosis

Exclusion Criteria:

* Psychological disorders

Primary outcomes:
measure: Brain-derived neurotrophic factor
timeFrame: 3 months
Secondary outcomes:
measure: Brain-derived neurotrophic factor
timeFrame: 1 year
measure: Vascular cell adhesion molecule-1
timeFrame: 3 months
measure: Orexin-A
timeFrame: 3 months
measure: Body components
timeFrame: 3 months
measure: Zung self-rating depression scale
timeFrame: 3 months
measure: 5-Item Geriatric Depression Scale
timeFrame: 3 months
measure: The Mini Mental State Examination (MMSE)
timeFrame: 3 months
measure: The Barthel index
timeFrame: 3 months
measure: Instrumental Activities of Daily Living (IADL)
timeFrame: 3 months
measure: ankle-brachial index
timeFrame: 3 months
Other outcomes:
Locations:
city: Taichung
country: Taiwan
facility: outpatient clinic of the Division of Endocrinology and Metabolism in Taichung Veterans General Hospital
city: Taichung
country: Taiwan
facility: Taichung Veterans General Hospital
Study officials:
References:
Clinical trial NCT05694403: Follow up of Stroke Patients by Neurologists and General Practitioners
Official title: Follow up of Stroke Patients by Neurologists and GP's: How Smooth is the Internal Communication and is There Room for Improvement?
Study type: OBSERVATIONAL
Overall status: NOT_YET_RECRUITING
Conditions: Stroke
Lead sponsor: Vrije Universiteit Brussel
Sponsor class: OTHER
First posted: 2023-01-23
Enrollment: 100
Sex: ALL
Minimum age (years): 24
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: OTHER
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Neurologists and general practitioners around Brussels

Brief summary: From the region around Brussels there are currently few data on how the post-stroke process take place and how satisfied the care providers are with it. For this reason, this survey is set up with the aim of examining four pillars: the epidemiology of stroke, communication between neurologists and GPs and satisfaction with it, secondary prevention of cardiovascular disease and control/treatment of the most common sequelae after stroke. In the latter two, the emphasis is on detection and treatment, and explicitly on whose task this is (neurologist versus GP), with the aim of verifying the mutual consensus on treatment and the subsequent detection of treatment shortcomings. This study will mainly consist of interviewing general practitioners and neurologists in the periphery of Brussels. This will be done by means of partly structured questionnaires, that will be send out to the medical professionals by contact with the central umbrella organisations of neurology in the hospitals and contact with the various general practitioners' practices (directly or through the multidisciplinary meetings per region). The questionnaires will be made up in google forms, as this programme allows efficient data processing, is eas-ily understandable for every participant and as no individual patient data will be processed.


Eligibility criteria: Inclusion Criteria:

* Neurologist and/or general practitioner

Exclusion Criteria:

* Not actively treating stroke patients

Primary outcomes:
measure: secondary prevention stroke: Antithrombotics
timeFrame: 1,5 - 2 years
measure: secondary prevention stroke: Hypertension
timeFrame: 1,5 - 2 years
measure: secondary prevention stroke: Smoking
timeFrame: 1,5 - 2 years
measure: secondary prevention stroke: Diabetes
timeFrame: 1,5 - 2 years
measure: secondary prevention stroke: general
timeFrame: 1,5 - 2 years
measure: sequelae of stroke: Fatigue
timeFrame: 1,5 - 2 years
measure: sequelae of stroke: Depression
timeFrame: 1,5 - 2 years
measure: sequelae of stroke: Sexual dyfunction
timeFrame: 1,5 - 2 years
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT00512603: Association Between Levels of D-Dimer, Fibrinogen and PAI-1 in Elderly Patients With Infection and Occurrence of Cardio- and Cerebro-vascular Disease After Discharge
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Infection
Acute Coronary Syndrome
Cerebrovascular Disease
Keywords: cerebro vascular event
Lead sponsor: Wolfson Medical Center
Sponsor class: OTHER_GOV
First posted: 2007-08-07
Enrollment: 52
Sex: ALL
Minimum age (years): 65
Standard ages: OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Elderly patients hospitalized due to infections

Brief summary: The association between the levels of d-dimer, fibrinogen and PAI-1 in plasma of elderly patients admitted to internal medicine departments because of infection and the occurrence of cardio- and cerebro-vascular disease after discharge


Eligibility criteria: Inclusion Criteria:

* Acute infection

Exclusion Criteria:

* Anticoagulant therapy

Primary outcomes:
measure: thrombosis
timeFrame: 24 months
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: Wolfson Medical Center
name: Asher Winder, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04408703: PRognOstiC valuE of rEd Density in Ulcerative Colitis
Official title: PRognOstiC valuE of rEd Density in Ulcerative Colitis: PROCEED-UC STUDY
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Ulcerative Colitis
Keywords: Endoscopy
Artificial intelligence
Image analysis
Precision medicine
Inflammatory bowel disease
Lead sponsor: Universitaire Ziekenhuizen KU Leuven
Sponsor class: OTHER
Collaborators: name: Sapporo Medical University
name: Imelda GI Clinical Research Center
First posted: 2020-05-29
Enrollment: 243
Sex: ALL
Minimum age (years): 16
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Patients with ulcerative colitis in clinical remission

Brief summary: Observational prospective multicenter study: baseline assessement of the disease activity by an automated endoscopic tool and follow up of 52 weeks to evaluate sustained clinical remission.


Eligibility criteria: Inclusion Criteria:

* Confirmed diagnosis of UC for at least 3 months
* Clinical remission with SCCAI \<3 at baseline and stable remission for the last 3 months
* Ability to give informed consent by the patient or legal representative in case of minority.

Exclusion Criteria:

* Any contraindication for sigmoidoscopy or undergoing biopsies of the rectosigmoid.
* Uncontrolled coagulopathy.
* Any planned change in UC related treatment (both escalation and de-escalation) after the baseline endoscopy
* Planned UC related surgery
* Previous subtotal or total colectomy
* Short bowel, ileostomy or colostomy
* Pregnancy at baseline
* Age younger than 16 years

Primary outcomes:
measure: sustained clinical remission
timeFrame: week 52
Secondary outcomes:
measure: endoscopic remission Mayo
timeFrame: week 52
measure: endoscopic remission UCEIS
timeFrame: week 52
Other outcomes:
measure: correlation biomarker
timeFrame: week 52
measure: correlation histological score
timeFrame: week 52
measure: correlation endoscopic score
timeFrame: week 52
Locations:
city: Bonheiden
country: Belgium
facility: Imelda GI clinical research center
city: Leuven
country: Belgium
facility: UZ Leuven
Study officials:
affiliation: UZ Leuven
name: Raf Bisschops, MD PhD
role: PRINCIPAL_INVESTIGATOR
affiliation: UZ Leuven
name: Peter Bossuyt, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Bossuyt P, Nakase H, Vermeire S, de Hertogh G, Eelbode T, Ferrante M, Hasegawa T, Willekens H, Ikemoto Y, Makino T, Bisschops R. Automatic, computer-aided determination of endoscopic and histological inflammation in patients with mild to moderate ulcerative colitis based on red density. Gut. 2020 Oct;69(10):1778-1786. doi: 10.1136/gutjnl-2019-320056. Epub 2020 Jan 8.
Clinical trial NCT02580903: Pulmonary Hypertension in Patients With Myeloproliferative Neoplasms
Official title: Pulmonary Hypertension in Patients With Philadelphia Chromosome Negative Myeloproliferative Neoplasms; an Observational Prospective Study
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Myeloproliferative Disorders
Pulmonary Hypertension
Lead sponsor: Odense University Hospital
Sponsor class: OTHER
First posted: 2015-10-20
Enrollment: 180
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients attending our outpatient clinic with Myeloproliferative Neoplasms

Brief summary: This is an observational prospective study aiming to clarify the prevalence of pulmonary hypertension in patients with Myeloproliferative Neoplasms and their prognosis.

All patients attending our department with the above mentioned neoplasms will be offered inclusion in this study. All will have an echo performed and patients identified as being at risk of pulmonary hypertension will be offered complete investigation as specified by the European Cardiology Association.

All patients will be followed up for a total of five years to identify prognosis.


Eligibility criteria: Inclusion Criteria:

* Myeloproliferative Neoplasms (PV, ET, PMF according to WHO classification)

Exclusion Criteria:

* Pregnancy
* Lack of informed consent
* Age \< 18 years
* Cognitive dysfunctions

Primary outcomes:
measure: Prevalence of pulmonary hypertension at initial presentation and first echo
timeFrame: Initial recruitment
Secondary outcomes:
measure: Mortality
timeFrame: 1 and 5 years
measure: Incidence of pulmonary hypertension while under follow-up
timeFrame: 5 years
Other outcomes:
Locations:
city: Odense
country: Denmark
facility: Odense University Hospital
Study officials:
affiliation: Odense University Hospital
name: Mette Brabrand, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00927303: The Spectralis-Cirrus Study
Official title: Comparison of Quality and Reproducibility of Retinal Thickness Measurements in Two Spectral Domain OCT- Machines
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Exudative Age Related Macular Degeneration
Keywords: retinal thickness
threshold algorithm
optical coherence tomography
Lead sponsor: The Ludwig Boltzmann Institute of Retinology and Biomicroscopic Laser Surgery
Sponsor class: OTHER
First posted: 2009-06-24
Enrollment: 110
Sex: ALL
Minimum age (years): 50
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: male or female persons aged more than 50 years with exudative age related macular degeneration

Brief summary: Retinal thickness measurement is one of the most important examinations in the follow up of exudative age-related macular degeneration. Prior studies have shown that there are a series of algorithm line failures in OCT examinations. This study is conducted to compare the quality of the examinations of to different spectral domain OCT machines concerning the positioning of algorithm lines. Furthermore the reproducibility of the examinations id tested, both machines provide different techniques to guarantee that in repeated examinations the same location is examined.


Eligibility criteria: Inclusion Criteria:

* Exudative age related macular degeneration

Exclusion Criteria:

* Macular pathologies other than age related macular degeneration (diabetic maculopathy, macular pucker, macular hole,
* Visualization of the macula not possible (dens cataract, vitreous haemorrhage)
* Not consented patients

Primary outcomes:
measure: Number of examinations with correctly set threshold algorithm lines
timeFrame: 1 day
Secondary outcomes:
measure: Differences of mean retinal thickness in the central region
timeFrame: 1 day
measure: Differences of retinal volume
timeFrame: 1 day
measure: Distance acuity
timeFrame: 1 day
measure: Age
timeFrame: 1 day
measure: Classification of the lesion
timeFrame: 1 day
Other outcomes:
Locations:
city: Vienna
country: Austria
facility: Ludwig Boltzmann Institute for Retinology and Biomicroscopic Lasersurgery
Study officials:
affiliation: Ludwig Boltzmann Institute for Retinology and Biomicroscopic Laser Surgery
name: Susanne Binder, MD, Prof
role: STUDY_CHAIR
References:
citation: Krebs I, Smretschnig E, Moussa S, Brannath W, Womastek I, Binder S. Quality and reproducibility of retinal thickness measurements in two spectral-domain optical coherence tomography machines. Invest Ophthalmol Vis Sci. 2011 Sep 1;52(9):6925-33. doi: 10.1167/iovs.10-6612.